NDC 70860-116-41 - Nafcillin
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 70860-116
- Requested NDC
- 70860-116-41
- Package NDCs from labels
- 70860-116-41, 70860-116-26
- Manufacturer
- Athenex Pharmaceutical Division, LLC.
- Effective date
- 2024-03-04
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| Nafcillin for Injection, USP (For Intramuscular or Intravenous Injection) | Athenex Pharmaceutical Division, LLC. | 2024-03-04 | HUMAN PRESCRIPTION DRUG LABEL |
FDA-Initiated Inactive NDC Indexing#
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 70860-116-26 | 2024-03-04 | C162847 | 48780-1 | 1030e364-fcc3-111a-e063-dadaa90a10e2 | Nafcillin for Injection, USP (For Intramuscular or Intravenous Injection) |
| 70860-116-26 | 2024-01-30 | C162847 | 48780-1 | 1030e364-fcc3-111a-e063-dadaa90a10e2 | Nafcillin for Injection, USP (For Intramuscular or Intravenous Injection) |
DailyMed Dashboard NDC Coverage#
DailyMed Billing Units#
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 70860-116-26 | EA - Each | 70860-116 | 8c5afc0a-e310-4857-8721-9d7d8714ec85 | 1 | 2018-09-05 |
| 70860-116-41 | EA - Each | 70860-116 | 268de5a6-45c0-4ccd-ae36-1206a1c2094c | 1 | 2019-04-11 |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Nafcillin | NAFCILLIN | WG Critical Care, LLC | 4d3b0076-3780-413f-9052-b23be5f18f01 | 2026-08-25 | Warnings, Adverse reactions | ANDA090560 49G3001BCK |
| Nafcillin | NAFCILLIN SODIUM | Heritage Pharmaceuticals Inc. d/b/a/ Avet Pharmaceuticals Inc. | 8a00624c-c436-4102-a042-dab54022bcc2 | 2026-07-28 | Warnings, Adverse reactions | ANDA090560 49G3001BCK |
| NAFCILLIN SODIUM | NAFCILLIN SODIUM | ONESOURCE SPECIALTY PHARMA LIMITED | 4b3b8e52-df96-4886-e063-6294a90ac63f | 2026-03-09 | Warnings, Adverse reactions | 49G3001BCK |
| NAFCILLIN SODIUM | NAFCILLIN SODIUM | Armas Pharmaceuticals Inc. | 090fda61-b9c8-640e-e063-6294a90a7363 | 2025-09-30 | Warnings, Adverse reactions | 49G3001BCK |
| Nafcillin | NAFCILLIN SODIUM | Eugia US LLC | 90717878-64cb-4ffc-90bc-7b4e81e3d1cd | 2025-08-16 | Warnings, Adverse reactions | 49G3001BCK |
| Nafcillin | NAFCILLIN SODIUM | Eugia US LLC | 8ec288e6-4d7f-4fea-a5ab-f9f337ebaa86 | 2025-08-16 | Warnings, Adverse reactions | 49G3001BCK |
| Nafcillin | NAFCILLIN SODIUM | Eugia US LLC | 34821770-929c-40ea-a9e4-d4405dc869e1 | 2025-08-12 | Warnings, Adverse reactions | 49G3001BCK |
| Nafcillin | NAFCILLIN SODIUM | Eugia US LLC | 0f21384c-0f82-4d99-a05c-6773d1ee4bcf | 2025-08-12 | Warnings, Adverse reactions | 49G3001BCK |
| Nafcillin | NAFCILLIN SODIUM | Avenacy Inc. | 0556378a-b794-4235-ba09-ebdc295e9092 | 2025-02-01 | Warnings, Adverse reactions | 49G3001BCK |
| NAFCILLIN | NAFCILLIN | Baxter Healthcare Corporation | cd2d18c5-95a2-4fb4-bd8b-b5d39e2da416 | 2024-12-06 | Warnings, Adverse reactions | 49G3001BCK |
| Nafcillin | NAFCILLIN SODIUM | NorthStar Rx, LLC | ae5fb012-4012-4063-b2e4-f1f927c6bf74 | 2024-07-09 | Warnings, Adverse reactions | 49G3001BCK |
| 12dde6de-9680-cb5e-e063-6294a90acede | 803fddee-c2d5-47e8-af7f-0caa38093ca6 | 2024-03-04 | Warnings, Adverse reactions | 12dde6de-9680-cb5e-e063-6294a90acede 803fddee-c2d5-47e8-af7f-0caa38093ca6 | ||
| Nafcillin | NAFCILLIN | NorthStar Rx, LLC | 91ebf84a-310f-4271-8446-5a10a877883a | 2024-02-27 | Warnings, Adverse reactions | 49G3001BCK |
| Nafcillin | NAFCILLIN | Fresenius Kabi USA, LLC | bbf0d8e4-b8e4-4958-b6b6-f0b9960f3b6a | 2019-06-12 | Warnings, Adverse reactions | 49G3001BCK |
| Nafcillin | NAFCILLIN SODIUM | Fresenius Kabi USA, LLC | 3c2581a1-8051-4d7a-a1f7-521248648dc9 | 2019-05-24 | Warnings, Adverse reactions | 49G3001BCK |
| Nafcillin | NAFCILLIN SODIUM | Fresenius Kabi USA, LLC | c39721a3-7b22-4720-9dbd-bc82f03d2af7 | 2019-05-17 | Warnings, Adverse reactions | 49G3001BCK |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.